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Expanding DP4: application to drug compounds
and automation†
Kristaps Ermanis,a Kevin E. B. Parkes,b Tatiana Agbackb and Jonathan M. Goodman*c
The DP4 parameter, which provides a conﬁdence level for NMR assignment, has been widely used to
help assign the structures of many stereochemically-rich molecules. We present an improved version of
the procedure, which can be downloaded as Python script instead of running within a web-browser, and
which analyses output from open-source molecular modelling programs (TINKER and NWChem) in
addition to being able to use output from commercial packages (Schrodinger’s Macromodel and Jaguar;
Gaussian). The new open-source workﬂow incorporates a method for the automatic generation of dia-
stereomers using InChI strings and has been tested on a range of new structures. This improved workﬂow
permits the rapid and convenient computational elucidation of structure and relative stereochemistry.
Introduction
Computational methods for the prediction of NMR spectra are
well established and have become an invaluable tool in the
structure elucidation.1 When DFT calculations are used to
predict the NMR spectra of candidate structures, the next step
is to decide which of the predictions match the experimental
NMR data best. Many diﬀerent ways to quantitatively evaluate
goodness of fit have been developed, including mean absolute
error, corrected mean absolute error and correlation coeﬃ-
cient. In addition to these, we have developed CP3 and DP4
statistical parameters which help choosing the correct struc-
ture when several sets or just one set of experimental NMR
data are available, respectively.2,3 Both of these parameters
generally appear to give higher confidence in the correct struc-
ture than other parameters. DP4 in particular has seen wide
use in structure elucidation of many complex natural pro-
ducts4 and also synthetic compounds.5
A typical NMR prediction process starts with a confor-
mational search on all of the isomers. DFT GIAO calculations
are then run on all low-energy conformers, the predicted shifts
are combined using Boltzmann weighting and finally, the DP4
analysis is employed to decide which structure is the most
likely to be correct. DP4 analysis achieves this by first empiri-
cally scaling all the predicted chemical shifts to remove any
systematic errors. Errors are then calculated for each of the
signals. Then, assuming that each error follows a normal or t
distribution with known parameters, the probability of encoun-
tering each error in a correct structure is calculated. Next, all of
the probabilities for signals in a candidate structure are multi-
plied to give the overall absolute probability, that the candidate
structure is the correct one. Finally, these resulting probabilities
are converted to a set of relative probabilities that each candi-
date structure is the correct one using Bayes’ theorem.
DP4 was originally developed for the elucidation of the rela-
tive stereochemistry of natural products. Drug compounds is
another other class of compounds that also exhibit diverse
stereochemistry. They inhabit a distinct chemical space charac-
terized by higher number of heteroatoms and aromatic
systems. While DP4 should in principle be applicable to any
organic compound, its performance in drug compounds is all
but untested.
So far in our investigations we have been using MacroModel6
for conformational searches and Jaguar7 or Gaussian8 for DFT
and GIAO calculations. However, there exist open-source
alternatives for both conformational search and for DFT calcu-
lations. Incorporation and validation of this software in the DP4
process would significantly increase its accessibility.
Results and discussion
Application to drug molecules
DP4 was originally developed with a focus on natural products
and their fragments.3 We wanted to explore the application of
the DP4 workflow in a less familiar chemical space. Drug com-
pounds occupy one such region – in general, they contain less
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stereocentres, but more heteroatoms and aromatic systems
when compared to natural products. A large portion of drug
compounds also contain basic nitrogen atoms or systems with
several possible tautomeric states, which can make the predic-
tion of NMR spectra challenging. For this study a selection of
stereochemically rich drug compounds from the Top 100
drugs was chosen (Fig. 1).9 The selected compounds all had
2–64 plausible diastereomers and had a well defined tauto-
meric state. Nucleoside analogs in particular were not
included in this study because of the potential tautomeric and
protonated states.
The compounds and their diastereomers were submitted to
MacroModel conformational search, all conformers with
energy less than 10 kJ mol−1 relative to the global minimum
were then submitted to DFT single point calculation and NMR
GIAO calculation10 using Gaussian quantum chemistry soft-
ware. Our earlier studies demonstrated that this protocol pro-
vides an eﬀective balance of precision and speed.3 Finally, the
predicted NMR shifts were submitted to DP4 analysis. For
mometasone, 4, and testosterone, 3, only the structures dia-
stereomeric at the peripheral stereocentres were considered. In
the case of tiotropium, 7, the epoxide chiral centres were
varied in concert, as the trans isomers would be too strained to
exist. For the rest of the compounds all possible diastereomers
were considered. The results of this study are shown in Fig. 2.
Ideally, the DP4 parameter will give 100% confidence for
the correct diastereoisomer, but all certainty beyond a random
selection is useful, and certainty on some stereocentres is
helpful. In the figure, the colours correspond to the utility of
the assignment. Dark blue is the probability of the completely
correct structure. The other colours relate to the utility – six
out of seven stereocentres correct is a better result than three
out of four. We note that all of the structures considered are
C1 symmetry, and so the number of diastereoisomers that
need to be considered is always 2N−1.
Early in our investigations it was found that inclusion of
the solvent in the DFT calculations reduced the errors of the
chemical shift prediction and improved the identification of
the correct diastereomer. Therefore the PCM solvent model11
was used for all NMR GIAO calculations. In most cases DP4 is
able to correctly determine the relative stereochemistry of
these compounds with good confidence and shows the gener-
ality and robustness of the DP4 approach. Even highly flexible
structures like rosuvastatin, 2, and formoterol, 1, were correctly
identified. In the case of ezetimibe, 8, however DP4 favoured
the structure epimeric at the remote OH centre as the most
likely with 98% confidence, with the correct structure as a
remote second most likely candidate. Similarly in the case of
Fig. 2 Overall DP4 probabilities assigned to drug compound diastereo-
mers using MacroModel and Gaussian. Only diastereomers with prob-
abilities greater than 0.1% shown.
Fig. 1 Stereochemically rich drug molecules selected for DP4 study. Diastereomer count shown. Diastereomers labelled with letters a–bl, a being
the correct diastereomer. Conﬁguration was varied at chiral centres marked with ‘*’.
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darunavir, 6, the most likely structure was identified as the one
with epimeric OH centre. However, the relative stereochemistry
of the remaining four stereocentres was identified correctly,
despite the flexible nature of the molecule. The case of simvas-
tatin, 5, was particularly challenging as this compound is quite
flexible and has seven stereocentres and 64 possible diastereo-
mers. Unfortunately this particular problem appears to be too
complex for the current DP4 methodology and the diastereo-
mers identified as likely candidates were completely diﬀerent
from the correct structure. However, the DP4 conclusion that
four diastereomers have significant probability may suggest the
challenge of this highly flexible structure to the user and thus
would likely not lead to incorrect conclusions.
Several of our previous studies have shown that optimi-
zation of the geometries at the DFT level provides only limited
improvement at high computational cost. We decided to test if
this still holds true on the compounds in the current dataset
and we chose two compounds with the most potential for
improvement – tiotropium, 7, and ezetimibe, 8. The geome-
tries were optimized at the same DFT level as used for shift cal-
culation and the DP4 analysis was repeated at a cost of
approximately 30-fold increase in the computational time. For
tiotropium, DFT optimization reduced the average corrected
NMR shift error by 0.27 ppm for carbon and by 0.02 ppm for
proton, and left the separate DP4 confidences based on carbon
and proton NMR essentially unchanged. However, the overall
confidence was increased from 14.7% to 68.2% because the
carbon and proton were now in conflict as to which is the
most likely structure and this let the correct structure emerge
as the overall top result. For ezetimibe, DFT optimization
reduced the average corrected NMR shift error by 0.77 ppm for
carbon, but increased the error by 0.01 ppm for proton. The
overall confidence improved from 2.8% to 72.0%. Therefore
improvement can be gained by optimizing the geometries at
the DFT level for these anomalous examples. However, the
computational cost makes this approach impractical in many
cases: to repeat the DP4 analysis with DFT optimization on
darunavir and simvastatin would require about 12 and 36 CPU
months on our desktop setup, respectively.
Overall the results from this study are very encouraging. In
majority of cases DP4 is capable of elucidating the relative
stereochemistry of the drug compounds despite the fact that
the statistical model was developed for natural products and
their fragments.
Integration of open-source software
Computing power nowadays is more accessible than ever and
this often means that costly software licences are a greater
barrier to the use of computational chemistry than the avail-
ability of hardware. This is particularly true for the occasional
users. To alleviate this problem in the context of structure elu-
cidation, we decided to test open-source software as alterna-
tives to MacroModel, Gaussian and Jaguar.
One well-known open-source DFT package with NMR GIAO
implementation is NWChem.12 We have previously shown that
the diﬀerences between Gaussian and Jaguar DFT packages do
not significantly aﬀect the outcome of DP4 calculations, and,
therefore, we hoped that the same would be true for NWChem.
Probably the most significant diﬀerence between Gaussian
and NWChem are the available solvent models. While Gaus-
sian has several versions of PCM models implemented, the
only solvent model available in NWChem is COSMO.13 It was
hoped that the diﬀerent solvent models would not cause large
diﬀerences to the chemical shift calculations. To test this,
NWChem was used for DP4 workflow and the process was
repeated for six drug molecules (Fig. 3). The results were very
similar to those achieved with Gaussian, with the mean absol-
ute diﬀerence in the predicted shifts being 0.34 ppm for
carbon and 0.08 ppm for proton NMR. This shows that
NWChem can be used in place of Jaguar or Gaussian with
little eﬀect on DP4 performance, using the standard workflow,
which uses molecular geometries generated by force-fields.
One significant diﬀerence was in the case of formoterol, 1.
While the MacroModel/Gaussian combination gives 81.9%
overall DP4 probability for the correct diastereomer, Macro-
Model/NWChem combination gives only 0.5% for the correct
structure. This arises from conflicting conclusions from
carbon and proton spectra in both cases. The proton data
gives high (>95%) confidence in the correct structure, while
carbon data gives high (>95%) confidence in the incorrect one.
The confidence in the correct proton assignment is slightly
lower in the NWChem case, probably because of the diﬀerent
solvent model. This causes the confidence in the carbon NMR
based assignment to rise and also causes a switch in the
overall assignment. In all other cases the overall DP4 probabil-
ities are very similar with the Gaussian version of the
workflow.
TINKER is an open-source molecular mechanics package14
which we tested as an alternative for MacroModel in perfom-
ing conformational searches. The performance of TINKER/
Gaussian workflow was tested by repeating the calculations on
the drug molecules (Fig. 4). In our experience TINKER confor-
mational searches were slower than the same searches run
using MacroModel and generated many more conformations.
Fig. 3 Overall DP4 probabilities assigned to drug compound diastereo-
mers using MacroModel and NWChem. Only diastereomers with prob-
abilities greater than 0.1% shown.
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As a result, we were not able to complete the calculations for
darunavir, 6, and simvastatin, 5. For the rest of the molecules,
however, the DP4 results are quite similar to the MacroModel
workflow and in general seem equally good at identifying the
correct diastereomer. For tiotropium, 7, the DP4 performance
improved the outcome and the confidence in the correct struc-
ture increased from 14.7% when using MacroModel to 60.9%
with TINKER. In contrast, the confidences for the correct dia-
stereomers of tadalafil, 10, and solifenacin, 9, were reduced.
Both structures can only have two diastereomers and in the
case of tadalafil the confidence in the correct one is only
50.5%, essentially having no predictive value. In the case of
solifenacin, the confidence was reduced even further to 42.8%.
The cause for these diﬀerences is most likely the diﬀerences in
the search algorithm implementations. On average, however,
the DP4 results appear to be of similar quality regardless of
the molecular mechanics software used.
Finally, the fully open-source version of the process was
tested using TINKER and NWChem. Calculations were run on
the same set of molecules as in the MacroModel/NWChem
case (Fig. 5). Overall the results appear to be very similar to the
previous results. As in the case of TINKER/Gaussian workflow,
results for solifenacin, 9, and tadalafil, 10, were indecisive. In
all other cases, however, the correct diastereomer was identi-
fied with high confidence. The average performance of this
workflow once again appears to be similar to the other three
investigated. This demonstrates a fully open-source version of
the DP4 workflow and should significantly improve its accessi-
bility to chemists in all areas of organic chemistry.
Automatic generation of diastereomers
The most common use of DP4 is for the determination of the
relative stereochemistry of complex molecules. The number of
possible diastereomers quickly increases with the number of
stereocentres and the manual input of the candidate structures
becomes cumbersome and error-prone. User-friendliness would
be significantly improved if all candidate diastereomers could be
generated from a single base structure. There has been little pre-
vious work on this problem and the solutions developed so far
are not general.15 We reasoned that the most straightforward
way of generating diastereomers would be through InChI
strings.16 InChIs are a compact and consistent way of represent-
ing chemical structures and because of the layered structure,
they are easy to manipulate by computer programs (Fig. 6).
Fig. 5 Overall DP4 probabilities assigned to drug compound diastereo-
mers using Tinker and NWChem. Only diastereomers with probabilities
greater than 0.1% shown.
Fig. 4 Overall DP4 probabilities assigned to drug compound diastereo-
mers using Tinker and Gaussian. Only diastereomers with probabilities
greater than 0.1% shown.
Fig. 6 Key features of InChI strings and their use in automatic diastereomer generation.
Paper Organic & Biomolecular Chemistry





















































































To generate diastereomers, the base candidate 3D structure
is first converted into an InChI string. This can be done using
one of several utilities and frameworks freely available online,
including IUPAC utilities,16 OpenBabel17 and Marvin MolCon-
verter.18 From this, InChI strings for diastereomeric structures
are generated by modifying the relative stereochemistry layer
to represent all possible combinations of the configurations.
Finally, InChIs are converted back into 3D structures. Several
utilities oﬀer this service, and we found that only Marvin Mol-
Converter, which is available as free software from Chem-
Axon,18 produced good 3D structures. After this, structures
could be immediately used in the DP4 process without any
further modification. Both the generation of all diastereomers
and diastereomers at particular chiral centres have been
implemented as a Python script with Marvin Molconverter as
the backend for the generation of InChI strings from struc-
tures and the generation of structures from InChI strings. This
process was successfully used in the drug study to generate all
the candidate structures. The only exception was tiotropium, 7,
because some of the automatically generated structures would
be too strained to be viable and manually drawn structures
were analyzed in this case.
Full automation of the workflow
Taking the idea of DP4 automation further, a Python appli-
cation PyDP4 was developed that integrates and automates the
whole process (Fig. 7). The application takes the 3D geometry
of the candidate structures as an SDF file and prepares the
input files for the conformational search done by either Macro-
Model or TINKER. After the completion of the conformational
searches, the low-energy conformations are selected and Gaus-
sian, Jaguar or NWChem input files are prepared and run.
Finally, it extracts the predicted NMR shifts, performs the
Boltzmann weighting and combines the computational NMR
data with the experimental NMR description and passes it on
to DP4 analysis. It is important to note that there is no user
interaction required after the submission of the initial 3D
structures and NMR spectra description.
The script also alleviates the shortcomings in TINKER con-
formation pruning. TINKER only removes duplicate confor-
mations based on energy; therefore the number of
conformations generated is much larger than in the case of
MacroModel. To keep the number of conformations submitted
to the DFT calculations down, we implemented RMSD pruning
of conformations. RMSD pruning works by calculating the
diﬀerences in atom positions in diﬀerent conformers and if
the RMSD value exceeds a chosen cut-oﬀ value, the confor-
mations are considered similar and one of the conformations
is discarded. This procedure requires the molecules to be
aligned and to achieve this, QTRFIT alignment algorithm was
also implemented in Python.19
All of these improvements in combination mean that DP4
structure elucidation and verification can now be done quickly
and easily. In our experience, a full elucidation of the relative
stereochemistry could be done with as little as one hour of
active user eﬀort. In principle, new developments in this area,
such as Sarotti’s recent modification of DP4,22 could be incor-
porated into a similar workflow.
Computational methods
All molecular mechanics calculations were performed using
either MacroModel6 (Version 9.9) or TINKER.14 All confor-
mational searches were done using MMFF force field20 and
Low Mode following search algorithms.21 The conformational
searches were done in the gas phase and the step count for
MacroModel was adjusted so that all low-energy conformers
were found at least 5 times.
Quantum mechanical calculations were carried out using
Gaussian ’09 8 and NWChem 6.5,12 B3LYP functional23 and
6-31G(d,p) basis set.24 PCM and COSMO solvent models were
used in the case of Gaussian and NWChem, respectively.11,13
NMR shielding constant calculations used the GIAO method.10
Calculation setup, data extraction and DP4 analysis were done
using the PyDP4 script written in Python 2.7. The script is
available on the group website (http://www-jmg.ch.cam.ac.uk/
tools/nmr), as well as on GitHub (https://github.com/
KristapsE/PyDP4) and in the ESI† under the MIT license.
TINKER, NWChem and Marvin Molconverter can be obtained
directly from their authors.
Conclusions
DP4 analysis has been applied to a novel chemical space and
was successfully used for assigning stereochemistry of drug
molecules. Open-source alternatives to MacroModel and Gaus-
sian/Jaguar were tested. TINKER molecular mechanics
package and NWChem ab initio software have been integrated
in a fully open-source DP4 workflow and this should signifi-
cantly improve accessibility of DP4 analysis.
A novel and general approach to automatic generation of
diastereomers was developed and relies on the use of InChI
strings. Finally, a full automation of the DP4 workflow has
reduced user interaction to a minimum – verification or eluci-
dation of the stereochemical structure can now be done in as
little as one hour of active eﬀort.
Fig. 7 Integrated and automated PyDP4 workﬂow for relative stereo-
chemistry elucidation.
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